WIL2 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | Wil2 is a human B lymphoblastoid cell line derived from peripheral blood B lymphocytes of an adult donor and subsequently immortalized through Epstein–Barr virus (EBV) transformation. As an EBV-positive suspension cell line, Wil2 exhibits characteristic features of activated B cells, including continuous proliferation, expression of B-cell surface markers, and the capacity for immunoglobulin synthesis. The cells grow in suspension as single cells or small clusters and are commonly maintained in standard lymphocyte culture conditions supplemented with serum. Phenotypically, Wil2 cells express typical B-lineage markers such as CD19, CD20, and surface immunoglobulins, along with activation-associated markers induced by EBV latent gene expression. The presence of EBV episomes drives proliferation and supports long-term culture, making this cell line a useful model for studying viral latency, B-cell activation, and host–virus interactions. Additionally, Wil2 has been used in immunological and molecular biology research focused on antibody production, antigen presentation, and signal transduction pathways in transformed B lymphocytes. While Wil2 serves as a representative EBV-transformed B-cell model, available published data on its detailed genetic background and functional specialization remain relatively limited compared to more extensively characterized lymphoblastoid lines. Researchers are encouraged to validate specific phenotypic or functional properties in their experimental context and consult updated databases or primary literature for the most current characterization data. |
|---|---|
| Organism | Human |
| Tissue | Spleen |
| Disease | Hereditary spherocytosis |
| Synonyms | WIL-2, Wil.2, WI-L2, Wi-L2 |
Characteristics
| Age | 5 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Cell type | B lymphoblast |
| Growth properties | Suspension |
Regulatory Data
| Citation | WIL2 (Cytion catalog number 302011) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_6544 |
Biomolecular Data
| Karyotype | 46, hypodiploid |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Seeding density | 1 x 105 cells/mL |
| Fluid renewal | 2 times per week |
| Post-Thaw Recovery | Fast |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Flask Coating | None |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|